This article is for informational and educational purposes only. Nothing here constitutes medical advice. Consult a licensed healthcare provider before using any supplement or injectable compound.
What Is NAD+ and Why Is It on a Peptide Site?
NAD+ (nicotinamide adenine dinucleotide) is not a peptide. It is a coenzyme — a small molecule made from vitamin B3 (niacin) — found in every living cell. We include it here because NAD+ has become one of the most commonly discussed compounds in the longevity and biohacking communities, frequently stacked alongside peptides, and understanding it is relevant to anyone exploring performance and healthspan optimization.
NAD+ participates in hundreds of enzymatic reactions. It is essential for converting food into cellular energy (ATP), repairing damaged DNA, regulating circadian rhythms, and maintaining the function of mitochondria — the energy-producing organelles in every cell.
Age-Related NAD+ Decline
Multiple studies have demonstrated that NAD+ levels decline with age, though the magnitude and rate of decline vary across tissues, measurement methods, and study populations. Some research suggests that tissue NAD+ levels may drop by 50% or more between ages 40 and 60, while other studies show more modest declines. The variability in findings reflects the difficulty of measuring intracellular NAD+ levels accurately — most blood tests measure plasma or whole-blood NAD+, which may not perfectly reflect tissue concentrations.
What is less disputed is the correlation between NAD+ decline and aging hallmarks: mitochondrial dysfunction, accumulation of DNA damage, chronic inflammation, and reduced cellular stress resilience. Whether NAD+ decline is a cause of aging, a consequence of it, or both, remains an active area of investigation. But the association is strong enough to motivate significant research into NAD+ restoration strategies.
Key Mechanisms: Sirtuins, PARPs, and CD38
NAD+ exerts its biological effects primarily through three families of enzymes that consume it as a substrate:
Sirtuins (SIRT1-7)
Sirtuins are a family of seven enzymes that regulate gene expression, DNA repair, metabolism, and inflammation. They require NAD+ to function — without adequate NAD+, sirtuin activity declines. SIRT1 and SIRT3 are the most studied in the longevity context. SIRT1 deacetylates proteins involved in stress resistance, fat metabolism, and insulin signaling. SIRT3 operates primarily in mitochondria, protecting against oxidative damage and maintaining energy production efficiency. Animal studies consistently show that boosting sirtuin activity extends healthspan, though human evidence is still emerging.
PARPs (Poly ADP-Ribose Polymerases)
PARPs are DNA repair enzymes that consume large amounts of NAD+ when activated. When DNA damage accumulates — from aging, UV exposure, toxins, or metabolic stress — PARPs consume NAD+ at an accelerated rate to facilitate repair. This creates a competition for available NAD+: heavy PARP activation can deplete NAD+ pools, leaving less available for sirtuins and other NAD+-dependent processes. This "NAD+ competition" is thought to be one mechanism linking DNA damage accumulation to broader aging dysfunction.
CD38
CD38 is an enzyme expressed on immune cells that degrades NAD+. Its activity increases with age and chronic inflammation, and it is now considered one of the primary drivers of age-related NAD+ decline. Research suggests that CD38 activity may account for a larger share of NAD+ consumption than sirtuins or PARPs in aged tissues. Some longevity researchers are exploring CD38 inhibitors (like apigenin, a flavonoid found in parsley and chamomile) as a strategy to preserve NAD+ levels, though clinical evidence for this approach is preliminary.
Routes of Administration
NAD+ can be delivered through several routes, each with different tradeoffs:
IV Infusion
Intravenous NAD+ delivers the molecule directly into the bloodstream, bypassing gastrointestinal degradation. Typical protocols involve 250-500mg infused over 2-4 hours, though some clinics offer higher doses. IV NAD+ is known for being uncomfortable — many recipients report chest tightness, nausea, and cramping during the infusion, which can be mitigated by slowing the drip rate. The direct bioavailability is the primary advantage, but the time, cost ($250-$1,000+ per session), and discomfort limit practicality for regular use.
Subcutaneous Injection
Subcutaneous NAD+ injection (typically 50-200mg) offers a compromise between IV and oral routes. It provides better bioavailability than oral precursors without the time commitment and discomfort of IV infusion. Injection site stinging is common. This route has gained popularity in the biohacking community, though published pharmacokinetic data specifically for subcutaneous NAD+ is limited.
Oral Precursors: NMN and NR
Because the NAD+ molecule is poorly absorbed intact through the gut, oral supplementation typically uses precursors that the body converts to NAD+. The two most popular are:
- NMN (Nicotinamide Mononucleotide): A direct precursor that enters cells via the Slc12a8 transporter and is converted to NAD+ in one enzymatic step. Typical doses range from 250mg to 1,000mg daily. The METRO trial (2024) showed that 12 weeks of NMN supplementation raised blood NAD+ levels in middle-aged adults, though clinical endpoint data remains limited.
- NR (Nicotinamide Riboside): Converted to NAD+ via a two-step pathway through NMN. Marketed as Tru Niagen and Niagen. Multiple human trials have confirmed it raises blood NAD+ levels. A 2018 study in Nature Communications showed NR was safe and well-tolerated in older adults, with measurable NAD+ elevation.
The NMN vs. NR debate is ongoing. Both raise NAD+ levels; whether one is clinically superior to the other for specific health outcomes has not been established in head-to-head human trials.
The SS-31 + NAD+ Stack
One of the more popular stacking protocols in the longevity community pairs NAD+ (or its precursors) with SS-31 (elamipretide), a mitochondria-targeted peptide. The rationale is complementary mechanisms: NAD+ supports the enzymatic machinery of mitochondrial function (sirtuins, electron transport chain), while SS-31 directly stabilizes cardiolipin in the inner mitochondrial membrane, improving electron transport efficiency and reducing oxidative damage.
The combination addresses mitochondrial dysfunction from two different angles — substrate availability (NAD+) and structural integrity (SS-31). Anecdotal reports from users describe improved energy, exercise recovery, and cognitive clarity, though controlled human data on this specific combination is lacking. Both compounds have individual clinical evidence supporting their mechanisms, which provides a reasonable theoretical basis for the stack.
Evidence Level
The evidence for NAD+ can be summarized as moderate overall, with significant variation by claim:
- Strong: Mechanistic data — NAD+ is essential for cellular function, and its decline with age is well-documented in the literature
- Moderate: Oral precursors (NMN/NR) do raise measurable blood NAD+ levels in human trials
- Limited: Whether raising NAD+ levels translates to meaningful clinical outcomes (longer life, fewer diseases, better function) in humans. Most lifespan and healthspan data comes from animal models
- Very limited: Comparative data on routes of administration, optimal dosing, and long-term safety of injectable NAD+
Safety Considerations
NAD+ and its precursors are generally well-tolerated, but several safety considerations warrant attention:
- Cancer contraindication: This is the most important safety concern. Cancer cells rely heavily on NAD+ for survival, proliferation, and resistance to therapy. Boosting NAD+ levels could theoretically support tumor growth or reduce the efficacy of chemotherapy and radiation. Anyone with active cancer, a recent cancer history, or elevated cancer risk should avoid NAD+ supplementation unless specifically cleared by their oncologist.
- Bipolar disorder caution: There are case reports and mechanistic reasons to be cautious about high-dose NAD+ in individuals with bipolar disorder. NAD+ can influence dopaminergic and serotonergic signaling, and rapid NAD+ elevation (particularly via IV) has been anecdotally associated with manic episodes. Individuals with bipolar disorder should consult their psychiatrist before using NAD+ in any form.
- Flushing and GI effects: High-dose niacin (another NAD+ precursor) causes flushing. NMN and NR are generally better tolerated, but some users report mild GI discomfort at higher doses.
- Drug interactions: See our peptide drug interactions guide for details on NAD+ and chemotherapy agents.
The Bottom Line
NAD+ occupies an interesting position in the longevity landscape: the mechanistic science is strong, the age-related decline is well-documented, and the preclinical evidence is encouraging. But the gap between "this molecule is important for cellular function" and "supplementing it will make you healthier or live longer" has not yet been fully bridged by rigorous human clinical trials.
For those who choose to explore NAD+ supplementation, oral precursors (NMN or NR) offer the most accessible and best-studied entry point. Injectable NAD+ provides higher bioavailability but comes with less clinical data, higher cost, and practical inconvenience. Whichever route you consider, the cancer contraindication and bipolar caution should be taken seriously.
Explore our peptide database for more compound profiles, and use our stack builder to explore how NAD+ fits into broader longevity protocols.